

**GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**LOK SABHA
UNSTARRED QUESTION NO.1515
TO BE ANSWERED ON 28TH JULY 2023**

HPV VACCINATION

**1515: DR. ALOK KUMAR SUMAN
SHRI CHANDRA SEKHAR BELLANA**

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) the status of the proposal of National Technical Advisory Group on Immunization (NTAGI) which recommended the introduction of HPV vaccine in the Universal Immunization Programme (UIP) along with the time by which it is likely to be finalized;
- (b) whether an extensive clinical trial regarding prevalence of the disease and efficacy of the vaccines have been undertaken before the submission of the said proposal by NTAGI;
- (c) if so, the timeline of the said trial, number of trials undertaken and the areas of the country where these trials have been conducted along with details of the expert committee under whom these trials have been conducted;
- (d) whether the Government have published the outcomes of the trials in domain of experts to obtain comprehensive inputs on the efficacy of the vaccine; and
- (e) if so, the details thereof?

**ANSWER
THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY
WELFARE
(PROF. SATYA PAL SINGH BAGHEL)**

- (a) to (e). In June 2022, based on fresh evidence on disease burden, experience of the Government of Sikkim on the introduction of HPV vaccine, National Technical Advisory Group on Immunization (NTAGI) recommended the introduction of HPV vaccine in the Universal Immunization Programme (UIP) with "a one-time catch-up for 9–14-year- old adolescent girls followed with routine introduction at 9 years of age. Based on the preclinical and clinical trial data of safety & immunogenicity and recommendations of Subject Experts Committee (SEC), the Indian regulator, Central Drugs Standard Control Organization (CDSCO) has approved one indigenously manufactured and two imported HPV Vaccines.
